Strategies for Phenotypic Drug Discovery Programs Using High-Content Imaging
About this webinar
Phenotypic screening has become a key strategy for identifying new therapeutics due to the ability to perform screens without knowing the target of interest. Phenotypic screens can be used to identify agents that reverse a disease state or to identify mechanisms of action of compounds in libraries. Strategies using multiplexed imaging approaches allow for high-content screening and analysis, thus increasing the depth of knowledge obtainable in a screen. Recent advantages in automation, miniaturization, imaging and analysis have dramatically increased the size of libraries and complexity of disease states which can be examined.
In this webinar, experts will discuss the current state of high-content screening for drug discovery. Discussion topics will include:
- Considerations for setting up phenotypic screens
- Resources necessary for cell biology, imaging and data analysis
- Current status of cell painting for drug discovery and future directions
Who should attend
- Drug discovery scientists
- Cellular imaging specialists
- Imaging analysts
What you will learn
- Considerations for setting up phenotypic screens
- Resources necessary for cell biology, imaging and data analysis
- Current status of cell painting for drug discovery and future directions
Featured Speakers
Matthew Betzenhauser, PhD
Matthew Betzenhauser, PhD is the team lead for the Cell Based Assay Technology team at Curia, formerly AMRI in Buffalo, NY. The Cell Based Assay Technology team leverages high content imaging and analysis in support of client programs to develop new models of disease and test novel therapeutics in oncology, immunology, neurobiology and other major human systems. Matthew earned his Ph.D. in Pharmacology at the University of Rochester where he used imaging-based assays to study calcium signaling pathways in cells.
Clark Driscoll, MS
Clark Driscoll, MS is a Research Scientist II who started his career at Curia more than five years ago, after completing his Master’s thesis. Clark has worked to develop novel live cell and fixed cell-based imaging assays that have been used in high-throughput screening campaigns.
George Opoku-Kusi, PhD
George Opoku-Kusi, PhD is a Research Scientist III who started at Curia in 2020 after completing doctoral and postdoctoral studies at the University of South Dakota where he developed novel imaging-based assays for drug discovery in primary human immune cells.
Partner for this event
Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s more than 3,700 employees at 29 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
Related webinars
More from Curia.
mRNA Vaccines: Quality Concepts in GMP IVT mRNA Development, Manufacturing & Analytics
Fast-Tracking Drug Development and Scale-Up in the Post-Covid World
A Customized Approach to mRNA Manufacturing
Building Efficiency into Biologics Formulations Development
T3P – A Versatile Peptide Coupling and Water Removal Reagent, Offering Several Process Advantages